Biogen profit rises 72% on multiple sclerosis therapy sales

Biogen Inc posted a 72% rise in quarterly profit and lifted its 2019 earnings forecast on Tuesday, boosted by higher sales of its top-selling multiple sclerosis therapy Tecfidera.